<DOC>
	<DOCNO>NCT02811809</DOCNO>
	<brief_summary>This study open men biochemical recurrence ( BCR , increase PSA ) follow local treatment prostate cancer . Androgen deprivation therapy ( ADT ) standard treatment option , effective 16-24 month number side effect impact quality life . These side effect may include fatigue , hot flushing , loss sex drive , brain fog , decrease bone mineral density , loss muscle mass , mild anemia ( low level red blood cell make people feel tired weak ) , diabetes ( low blood sugar ) , heart disease , metabolic syndrome ( sometimes call `` pre-diabetes '' include obesity , increase blood pressure , high level cholesterol triglyceride blood ) , risk fracture . An alternative continuous ADT intermittent administration , patient give `` break '' ADT let testosterone level return baseline . There number potential benefit intermittent hormone therapy ( IHT ) : ( 1 ) long time development resistance ; ( 2 ) improve patient quality life owe recovery adverse effect , particularly sexual function ; ( 3 ) substantial cost saving owe less time spend receive medication . Leuprolide name ADT / IHT drug . Apalutamide investigational drug , mean approve Food Drug Administration ( FDA ) . It antitumor drug , take mouth . The purpose study determine ability Apalutamide extend time first two injection leuprolide improve quality life . This study also look safety Apalutamide effect Apalutamide prostate cancer . Men randomize ( like flip coin ) receive : - Group A : Leuprolide + Apalutamide - Group B : Leuprolide ( second leuprolide injection ) , leuprolide + Apalutamide 45 men Group A 21 men Group B. Leuprolide give intramuscular shot last 3 month intermittently Apalutamide take mouth ( 4 tablet ) daily . Each cycle 4 week long . Intermittent treatment Apalutamide + leuprolide continue continuous leuprolide need maintain undetectable PSA level ( i.e. , PSA level rise undetectable level unless leuprolide give without pause , every 3 month ) .</brief_summary>
	<brief_title>Apalutamide Plus Intermittent Hormone Therapy Versus Intermittent Hormone Therapy Alone Prostate Cancer</brief_title>
	<detailed_description>Prostate-specific antigen ( PSA ) sensitive specific biomarker prostate tissue . Monitoring PSA local treatment prostate cancer assist identify patient increase PSA ( biochemical recurrence [ BCR ] ) despite symptom , sign , evidence radiographic metastatic disease . This subpopulation patient refer `` biochemical failure . '' Androgen deprivation therapy ( ADT ) standard treatment option , effective 16-24 month number side effect impact quality life . These side effect may include fatigue , hot flushing , loss sex drive , brain fog , decrease bone mineral density , loss muscle mass , mild anemia , diabetes , heart disease , metabolic syndrome risk fracture . An alternative continuous ADT intermittent administration , patient give `` break '' ADT let testosterone level return baseline . There number potential benefit intermittent hormone therapy ( IHT ) : ( 1 ) long time development resistance , owe removal constant pressure cause fast mutation resistant cell ; ( 2 ) improve patient quality life owe recovery adverse effect , particularly sexual function ; ( 3 ) substantial cost saving owe less time spend receive medication . Leuprolide name ADT / IHT drug . Apalutamide investigational antitumor drug , take mouth . It synthetic compound rationally design bind androgen receptor ( high affinity enzalutamide bicalutamide ) , prevent nuclear translocation DNA binding , induce apoptosis . It great antitumor activity lower dose , achieve steady-state level low dose , accumulate tumor tissue without building brain , increase effectiveness decrease risk seizure . Apalutamide 's mechanism action give potential extend time PSA increase intermittent ADT , delay necessity continuous ADT . Investigators assess potential application intermittent ADT plus Apalutamide participant BCR . This study elucidate potential regimen reduce burden adverse event continuous ADT delay development hormone resistance . This randomize crossover study intend determine interval ADT administration achievable supportive Apalutamide treatment . Investigators ass significance time PSA recurrence , time next leuprolide injection , time testosterone recovery , duration testosterone recovery , time biochemical recurrence , percentage men develop biochemical recurrence , number detectable CTCs , quality life measure . Treatment 66 participant 2:1 randomize crossover - 45 IHT + apalutamide:21 IHT second leuprolide injection , IHT + apalutamide Apalutamide + IHT Participants treat 240 mg ( 4 60 mg tablet ) oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently . IHT Participants receive 22.5 mg 3-month depot intramuscular leuprolide PSA progression , receive 240 mg oral Apalutamide daily plus 22.5 mg 3-month depot intramuscular leuprolide intermittently . Participants remain study continuous ADT require maintain castrate PSA level ( i.e. , leuprolide need every 3 month maintain PSA &lt; 1 ng/dL ) .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Hormones</mesh_term>
	<mesh_term>Leuprolide</mesh_term>
	<criteria>Age ≥ 18 year Patients diagnosis adenocarcinoma prostate Patients BCR ( PSA become detectable , absolute value ≥1 ) follow prostatectomy evidence metastatic disease base radiographic assessment . Patients BCR follow radiation therapy radiographic involvement per mpMRI CT ( RTOGASTRO Phoenix criterion ) , size pelvic node ≤1 cm , whose MRIdirected prostate biopsy negative . Patients must free serious comorbidity determine investigator . Clinical laboratory value screen : Serum testosterone level ≥150 ng/dL Hemoglobin ≥9.0 g/dL , independent transfusion and/or growth factor within 3 month prior randomization Platelet count ≥100,000 /µL independent transfusion and/or growth factor within 3 month prior randomization Serum albumin ≥3.0 g/dL GFR &gt; 45 mL/min Serum potassium ≥3.5 mmol/L Serum total bilirubin ≤1.5 × ULN ( Note : In subject Gilbert 's syndrome , total bilirubin &gt; 1.5 × ULN , measure direct indirect bilirubin direct bilirubin ≤1.5 × ULN , subject may eligible ) Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) &lt; 2.5 × ULN Medications know low seizure threshold ( see list prohibit med , Appendix 3 ) must discontinue substitute least 4 week prior study entry . Agrees use condom ( even men vasectomy ) another effective method birth control sex woman childbearing potential agrees use condom sex woman pregnant study drug 3 month follow last dose study drug . Must also agree donate sperm study 3 month receive last dose study drug . Written , inform consent participate study . PSA double time &gt; 12 month Positive HIV chronic hepatitis B hepatitis C infection Another primary malignancy remission least 2 year . Nonmelanoma skin cancer allow . Use herbal product may decrease PSA level ( e.g. , saw palmetto ) systemic corticosteroid great equivalent 10 mg prednisone per day within 4 week screen laboratory study . Any condition , include concurrent medical condition , social circumstance drug dependency , opinion investigator could compromise patient safety and/or compliance study requirement History follow : Seizure know condition may predispose seizure ( e.g . prior stroke within 1year randomization , brain arteriovenous malformation , Schwannoma , meningioma , benign CNS meningeal disease may require treatment surgery radiation therapy ) Severe unstable angina , myocardial infarction , symptomatic congestive heart failure , arterial venous thromboembolic event ( eg , pulmonary embolism , cerebrovascular accident include transient ischemic attack ) , clinically significant ventricular arrhythmia within 6 month prior randomization Any condition opinion investigator , would preclude participation study Current evidence following : Uncontrolled hypertension Gastrointestinal disorder affect absorption Active infection ( eg , human immunodeficiency virus [ HIV ] viral hepatitis ) Any condition opinion investigator , would preclude participation study</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Prostate cancer</keyword>
	<keyword>Apalutamide</keyword>
	<keyword>IHT</keyword>
	<keyword>BCR</keyword>
	<keyword>Biochemical recurrence</keyword>
	<keyword>intermittent hormone therapy</keyword>
</DOC>